| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 174 | 2025 | 1980 | 18.320 |
Why?
|
| Pulmonary Artery | 133 | 2025 | 1134 | 9.800 |
Why?
|
| Hypoxia | 104 | 2025 | 1199 | 8.610 |
Why?
|
| Fibroblasts | 55 | 2025 | 1034 | 7.430 |
Why?
|
| Muscle, Smooth, Vascular | 61 | 2025 | 452 | 5.290 |
Why?
|
| Vascular Remodeling | 24 | 2025 | 205 | 4.780 |
Why?
|
| Cattle | 106 | 2025 | 1000 | 3.820 |
Why?
|
| Lung | 79 | 2025 | 4109 | 2.940 |
Why?
|
| Myocytes, Smooth Muscle | 25 | 2025 | 266 | 2.910 |
Why?
|
| Animals | 262 | 2025 | 38058 | 2.630 |
Why?
|
| Macrophages | 22 | 2025 | 1511 | 2.230 |
Why?
|
| Endothelial Cells | 32 | 2025 | 869 | 2.200 |
Why?
|
| Pulmonary Circulation | 29 | 2022 | 430 | 2.170 |
Why?
|
| Ventricular Function, Right | 14 | 2025 | 297 | 2.110 |
Why?
|
| Macrophage Activation | 5 | 2021 | 193 | 1.970 |
Why?
|
| Ventricular Dysfunction, Right | 9 | 2025 | 248 | 1.750 |
Why?
|
| Cells, Cultured | 65 | 2025 | 4154 | 1.750 |
Why?
|
| Vasa Vasorum | 13 | 2023 | 37 | 1.690 |
Why?
|
| Disease Models, Animal | 49 | 2025 | 4557 | 1.640 |
Why?
|
| Macrophages, Alveolar | 11 | 2024 | 368 | 1.600 |
Why?
|
| Sirtuin 3 | 2 | 2024 | 60 | 1.580 |
Why?
|
| Endothelium, Vascular | 23 | 2020 | 965 | 1.550 |
Why?
|
| Heart Ventricles | 18 | 2025 | 760 | 1.530 |
Why?
|
| Cellular Reprogramming | 5 | 2025 | 103 | 1.530 |
Why?
|
| Familial Primary Pulmonary Hypertension | 12 | 2025 | 197 | 1.500 |
Why?
|
| Adventitia | 9 | 2025 | 43 | 1.480 |
Why?
|
| Animals, Newborn | 52 | 2016 | 902 | 1.430 |
Why?
|
| Cell Proliferation | 34 | 2023 | 2496 | 1.430 |
Why?
|
| Cell Hypoxia | 14 | 2015 | 247 | 1.390 |
Why?
|
| Lung Diseases | 11 | 2023 | 787 | 1.380 |
Why?
|
| Rats | 63 | 2024 | 5597 | 1.370 |
Why?
|
| Ventricular Remodeling | 7 | 2025 | 276 | 1.370 |
Why?
|
| Signal Transduction | 38 | 2024 | 5226 | 1.330 |
Why?
|
| Superoxide Dismutase | 11 | 2025 | 301 | 1.330 |
Why?
|
| Hypertrophy, Right Ventricular | 15 | 2023 | 150 | 1.220 |
Why?
|
| Cell Division | 38 | 2005 | 766 | 1.210 |
Why?
|
| Phenotype | 31 | 2024 | 3162 | 1.150 |
Why?
|
| Humans | 181 | 2025 | 144759 | 1.070 |
Why?
|
| Blood Vessels | 12 | 2013 | 171 | 1.040 |
Why?
|
| Biphenyl Compounds | 2 | 2024 | 68 | 1.040 |
Why?
|
| NAD | 2 | 2024 | 81 | 1.030 |
Why?
|
| Inflammation | 28 | 2025 | 2878 | 1.010 |
Why?
|
| Protein Kinase C | 14 | 2014 | 252 | 1.000 |
Why?
|
| Monocytes | 9 | 2025 | 538 | 0.990 |
Why?
|
| Mice | 50 | 2025 | 18339 | 0.960 |
Why?
|
| Pneumonia | 9 | 2022 | 631 | 0.950 |
Why?
|
| Complement System Proteins | 4 | 2025 | 316 | 0.940 |
Why?
|
| MicroRNAs | 6 | 2021 | 701 | 0.920 |
Why?
|
| Chronic Disease | 19 | 2020 | 1813 | 0.900 |
Why?
|
| Glycolysis | 9 | 2025 | 339 | 0.900 |
Why?
|
| Mice, Inbred C57BL | 29 | 2025 | 5992 | 0.900 |
Why?
|
| Lignans | 1 | 2024 | 12 | 0.870 |
Why?
|
| Adenosine Triphosphate | 7 | 2020 | 498 | 0.860 |
Why?
|
| Cell Movement | 11 | 2019 | 965 | 0.840 |
Why?
|
| Rats, Sprague-Dawley | 30 | 2024 | 2527 | 0.830 |
Why?
|
| Vascular Stiffness | 7 | 2023 | 486 | 0.810 |
Why?
|
| Endothelium | 3 | 2020 | 119 | 0.790 |
Why?
|
| Transcriptome | 4 | 2024 | 1045 | 0.790 |
Why?
|
| Cellular Microenvironment | 2 | 2021 | 94 | 0.780 |
Why?
|
| Mesoderm | 4 | 2011 | 150 | 0.770 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 3 | 2017 | 17 | 0.770 |
Why?
|
| Mitochondria | 7 | 2023 | 984 | 0.760 |
Why?
|
| Extracellular Vesicles | 2 | 2023 | 171 | 0.740 |
Why?
|
| Culture Media, Conditioned | 6 | 2023 | 111 | 0.740 |
Why?
|
| Gene Expression Profiling | 6 | 2024 | 1782 | 0.740 |
Why?
|
| Hemodynamics | 19 | 2025 | 1121 | 0.730 |
Why?
|
| Neovascularization, Pathologic | 6 | 2020 | 286 | 0.720 |
Why?
|
| Actins | 11 | 2018 | 425 | 0.720 |
Why?
|
| PPAR gamma | 4 | 2018 | 176 | 0.720 |
Why?
|
| Histone Deacetylase Inhibitors | 8 | 2023 | 220 | 0.720 |
Why?
|
| Male | 118 | 2025 | 72315 | 0.710 |
Why?
|
| Gene Expression Regulation | 20 | 2021 | 2608 | 0.710 |
Why?
|
| Peptidyl-Dipeptidase A | 6 | 2023 | 56 | 0.700 |
Why?
|
| Connective Tissue | 6 | 2011 | 39 | 0.680 |
Why?
|
| Stem Cells | 8 | 2015 | 626 | 0.670 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2017 | 18 | 0.670 |
Why?
|
| Pyruvate Kinase | 2 | 2017 | 28 | 0.660 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2018 | 219 | 0.650 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 358 | 0.650 |
Why?
|
| Epigenesis, Genetic | 5 | 2023 | 684 | 0.650 |
Why?
|
| Immediate-Early Proteins | 4 | 2006 | 48 | 0.640 |
Why?
|
| Stress, Mechanical | 12 | 2025 | 494 | 0.640 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2023 | 381 | 0.630 |
Why?
|
| Histone Deacetylases | 7 | 2023 | 210 | 0.630 |
Why?
|
| Inflammation Mediators | 5 | 2018 | 509 | 0.630 |
Why?
|
| Endothelin-1 | 5 | 2012 | 184 | 0.620 |
Why?
|
| Tropoelastin | 8 | 1999 | 11 | 0.620 |
Why?
|
| Cell Differentiation | 14 | 2018 | 2050 | 0.620 |
Why?
|
| Urate Oxidase | 1 | 2019 | 13 | 0.610 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 10 | 2023 | 297 | 0.600 |
Why?
|
| Vasoconstriction | 13 | 2020 | 217 | 0.600 |
Why?
|
| Gout | 1 | 2019 | 35 | 0.590 |
Why?
|
| Neovascularization, Physiologic | 8 | 2021 | 194 | 0.580 |
Why?
|
| Gene Expression | 14 | 2020 | 1490 | 0.580 |
Why?
|
| Blood Pressure | 24 | 2021 | 1769 | 0.580 |
Why?
|
| Extracellular Matrix | 10 | 2025 | 553 | 0.580 |
Why?
|
| Mice, Knockout | 16 | 2025 | 3121 | 0.570 |
Why?
|
| RNA, Messenger | 29 | 2020 | 2832 | 0.560 |
Why?
|
| Vasodilator Agents | 8 | 2023 | 331 | 0.560 |
Why?
|
| Collagen | 11 | 2019 | 456 | 0.560 |
Why?
|
| Twist-Related Protein 1 | 1 | 2018 | 9 | 0.550 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2020 | 380 | 0.540 |
Why?
|
| Polyethylene Glycols | 3 | 2020 | 654 | 0.540 |
Why?
|
| Complement Activation | 2 | 2024 | 411 | 0.530 |
Why?
|
| Up-Regulation | 9 | 2021 | 851 | 0.530 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 893 | 0.530 |
Why?
|
| Cell Plasticity | 1 | 2018 | 37 | 0.520 |
Why?
|
| rho-Associated Kinases | 6 | 2021 | 83 | 0.520 |
Why?
|
| Tissue Scaffolds | 3 | 2017 | 223 | 0.520 |
Why?
|
| Hemoglobins | 5 | 2019 | 384 | 0.510 |
Why?
|
| Cytokines | 11 | 2023 | 2061 | 0.510 |
Why?
|
| Transforming Growth Factor beta | 9 | 2023 | 479 | 0.510 |
Why?
|
| Epoprostenol | 6 | 2010 | 131 | 0.510 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 383 | 0.500 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2007 | 26 | 0.500 |
Why?
|
| Vasculitis | 2 | 2014 | 69 | 0.500 |
Why?
|
| Elastin | 11 | 2019 | 79 | 0.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2014 | 557 | 0.490 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2016 | 11 | 0.490 |
Why?
|
| Protein Kinases | 5 | 2007 | 315 | 0.490 |
Why?
|
| Energy Metabolism | 3 | 2017 | 935 | 0.490 |
Why?
|
| Elastic Modulus | 4 | 2020 | 121 | 0.490 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2016 | 38 | 0.480 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 1795 | 0.480 |
Why?
|
| DNA-Binding Proteins | 5 | 2016 | 1499 | 0.480 |
Why?
|
| Nuclear Proteins | 5 | 2020 | 748 | 0.480 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2016 | 62 | 0.480 |
Why?
|
| Anemia, Sickle Cell | 4 | 2023 | 312 | 0.470 |
Why?
|
| Heart Failure | 5 | 2023 | 2323 | 0.470 |
Why?
|
| Mitogens | 4 | 2009 | 55 | 0.470 |
Why?
|
| Pulmonary Veins | 6 | 2019 | 105 | 0.470 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2021 | 214 | 0.460 |
Why?
|
| Myocytes, Cardiac | 5 | 2021 | 556 | 0.460 |
Why?
|
| Sildenafil Citrate | 3 | 2023 | 60 | 0.460 |
Why?
|
| Altitude | 9 | 2018 | 473 | 0.460 |
Why?
|
| Bioprosthesis | 1 | 2015 | 40 | 0.450 |
Why?
|
| Microvessels | 4 | 2025 | 99 | 0.450 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2021 | 28 | 0.450 |
Why?
|
| Myocardial Contraction | 2 | 2016 | 298 | 0.450 |
Why?
|
| Tissue Engineering | 2 | 2020 | 442 | 0.450 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 50 | 0.440 |
Why?
|
| rhoA GTP-Binding Protein | 3 | 2019 | 76 | 0.440 |
Why?
|
| Early Growth Response Protein 1 | 4 | 2011 | 32 | 0.440 |
Why?
|
| Materials Testing | 2 | 2017 | 354 | 0.440 |
Why?
|
| Tunica Media | 5 | 2003 | 37 | 0.430 |
Why?
|
| Growth Substances | 6 | 2003 | 140 | 0.430 |
Why?
|
| Hypertension | 5 | 2018 | 1263 | 0.430 |
Why?
|
| Pulmonary Edema | 4 | 2019 | 106 | 0.420 |
Why?
|
| Reactive Oxygen Species | 6 | 2021 | 621 | 0.420 |
Why?
|
| Extracellular Space | 5 | 2011 | 120 | 0.420 |
Why?
|
| Allyl Compounds | 2 | 2024 | 26 | 0.420 |
Why?
|
| MAP Kinase Signaling System | 5 | 2012 | 310 | 0.420 |
Why?
|
| Platelet Activation | 3 | 2025 | 104 | 0.410 |
Why?
|
| Paracrine Communication | 4 | 2016 | 67 | 0.410 |
Why?
|
| Pulmonary Alveoli | 5 | 2005 | 383 | 0.400 |
Why?
|
| Thrombospondin 1 | 4 | 2025 | 28 | 0.400 |
Why?
|
| Respirovirus Infections | 2 | 2005 | 14 | 0.400 |
Why?
|
| Antihypertensive Agents | 4 | 2019 | 510 | 0.390 |
Why?
|
| Phenols | 2 | 2024 | 114 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 623 | 0.390 |
Why?
|
| Metabolome | 3 | 2021 | 384 | 0.390 |
Why?
|
| Myeloid Cells | 2 | 2011 | 148 | 0.380 |
Why?
|
| Myocardium | 6 | 2019 | 939 | 0.380 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2012 | 12 | 0.380 |
Why?
|
| Tunica Intima | 6 | 2019 | 79 | 0.380 |
Why?
|
| Bronchopulmonary Dysplasia | 4 | 2005 | 410 | 0.380 |
Why?
|
| Renin-Angiotensin System | 1 | 2013 | 78 | 0.380 |
Why?
|
| Pressure | 3 | 2019 | 225 | 0.380 |
Why?
|
| Enzyme Activation | 13 | 2012 | 766 | 0.370 |
Why?
|
| Disease Susceptibility | 4 | 2021 | 348 | 0.370 |
Why?
|
| Forkhead Transcription Factors | 3 | 2023 | 202 | 0.370 |
Why?
|
| Osteopontin | 1 | 2012 | 34 | 0.370 |
Why?
|
| Isoenzymes | 9 | 2017 | 299 | 0.360 |
Why?
|
| Vascular Resistance | 13 | 2025 | 367 | 0.360 |
Why?
|
| Microcirculation | 4 | 2025 | 138 | 0.360 |
Why?
|
| Arteritis | 1 | 2012 | 25 | 0.350 |
Why?
|
| Female | 59 | 2025 | 78271 | 0.350 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 60 | 0.350 |
Why?
|
| Models, Cardiovascular | 8 | 2025 | 195 | 0.350 |
Why?
|
| Coronary Vessels | 2 | 2025 | 251 | 0.350 |
Why?
|
| Complement C3 | 2 | 2025 | 191 | 0.350 |
Why?
|
| Phosphorylation | 10 | 2012 | 1732 | 0.340 |
Why?
|
| Oxidation-Reduction | 6 | 2017 | 1087 | 0.340 |
Why?
|
| Blood Platelets | 3 | 2025 | 400 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2023 | 474 | 0.330 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2007 | 35 | 0.330 |
Why?
|
| Cattle Diseases | 4 | 2015 | 26 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 7 | 2012 | 138 | 0.330 |
Why?
|
| Phagocytes | 1 | 2011 | 81 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2020 | 436 | 0.330 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2011 | 80 | 0.320 |
Why?
|
| Airway Remodeling | 1 | 2011 | 64 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 7 | 2012 | 175 | 0.320 |
Why?
|
| Apoptosis | 8 | 2021 | 2430 | 0.320 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 4 | 2020 | 19 | 0.320 |
Why?
|
| Myofibromatosis | 2 | 2001 | 10 | 0.320 |
Why?
|
| Fibrosis | 6 | 2023 | 548 | 0.310 |
Why?
|
| Disease Progression | 4 | 2019 | 2847 | 0.310 |
Why?
|
| Glucosephosphate Dehydrogenase | 3 | 2020 | 69 | 0.310 |
Why?
|
| Oxygen | 8 | 2018 | 995 | 0.310 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2009 | 20 | 0.310 |
Why?
|
| Acute Lung Injury | 2 | 2023 | 303 | 0.310 |
Why?
|
| Rats, Inbred WKY | 6 | 2015 | 37 | 0.310 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2009 | 26 | 0.300 |
Why?
|
| In Situ Hybridization | 10 | 2005 | 319 | 0.300 |
Why?
|
| STAT1 Transcription Factor | 1 | 2009 | 68 | 0.300 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 4 | 2021 | 52 | 0.300 |
Why?
|
| Arterial Pressure | 4 | 2019 | 136 | 0.300 |
Why?
|
| Vascular Diseases | 4 | 2019 | 251 | 0.300 |
Why?
|
| Schistosomiasis | 3 | 2024 | 49 | 0.290 |
Why?
|
| Time Factors | 16 | 2021 | 7173 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2003 | 292 | 0.280 |
Why?
|
| Fetus | 10 | 2015 | 803 | 0.280 |
Why?
|
| Cell Communication | 4 | 2017 | 324 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 983 | 0.280 |
Why?
|
| Citric Acid Cycle | 3 | 2020 | 59 | 0.280 |
Why?
|
| Receptors, Endothelin | 2 | 2005 | 50 | 0.270 |
Why?
|
| Chemokine CCL2 | 5 | 2025 | 115 | 0.270 |
Why?
|
| Bromodeoxyuridine | 4 | 2003 | 79 | 0.270 |
Why?
|
| Hyaluronic Acid | 2 | 2025 | 208 | 0.270 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2019 | 251 | 0.270 |
Why?
|
| Persistent Fetal Circulation Syndrome | 4 | 2015 | 138 | 0.270 |
Why?
|
| Respiratory Tract Infections | 2 | 2004 | 397 | 0.260 |
Why?
|
| Transcription Factors | 8 | 2020 | 1741 | 0.260 |
Why?
|
| Autocrine Communication | 2 | 2009 | 38 | 0.260 |
Why?
|
| Bleomycin | 4 | 2019 | 253 | 0.260 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2025 | 60 | 0.260 |
Why?
|
| Mitochondrial Proteins | 2 | 2023 | 262 | 0.260 |
Why?
|
| Infant | 17 | 2021 | 10034 | 0.260 |
Why?
|
| Hydrogels | 3 | 2020 | 700 | 0.260 |
Why?
|
| Pulmonary Fibrosis | 3 | 2023 | 395 | 0.260 |
Why?
|
| Vasodilation | 4 | 2019 | 523 | 0.250 |
Why?
|
| Immunohistochemistry | 12 | 2005 | 1716 | 0.250 |
Why?
|
| Proteins | 7 | 2023 | 1021 | 0.250 |
Why?
|
| Angiotensin II | 4 | 2013 | 97 | 0.250 |
Why?
|
| Muscle Contraction | 6 | 2018 | 429 | 0.250 |
Why?
|
| Leukocytes | 3 | 2019 | 295 | 0.250 |
Why?
|
| Biomimetic Materials | 2 | 2018 | 76 | 0.250 |
Why?
|
| Neprilysin | 2 | 2009 | 47 | 0.250 |
Why?
|
| Pulsatile Flow | 5 | 2014 | 55 | 0.240 |
Why?
|
| Infant, Premature | 2 | 2017 | 611 | 0.240 |
Why?
|
| Dendritic Cells | 3 | 2024 | 499 | 0.240 |
Why?
|
| Nitric Oxide | 7 | 2021 | 897 | 0.240 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2018 | 920 | 0.240 |
Why?
|
| Superoxides | 2 | 2017 | 204 | 0.240 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2023 | 389 | 0.240 |
Why?
|
| Mechanotransduction, Cellular | 4 | 2023 | 122 | 0.240 |
Why?
|
| Aorta, Thoracic | 4 | 2017 | 286 | 0.240 |
Why?
|
| Cardiac Catheterization | 5 | 2023 | 560 | 0.240 |
Why?
|
| Schistosoma | 3 | 2024 | 28 | 0.240 |
Why?
|
| Image Cytometry | 1 | 2025 | 12 | 0.230 |
Why?
|
| Blotting, Western | 7 | 2012 | 1187 | 0.230 |
Why?
|
| Sendai virus | 1 | 2005 | 6 | 0.230 |
Why?
|
| Coculture Techniques | 4 | 2021 | 246 | 0.230 |
Why?
|
| Endothelin Receptor Antagonists | 3 | 2005 | 62 | 0.230 |
Why?
|
| Infant, Newborn | 17 | 2015 | 6429 | 0.230 |
Why?
|
| Herpesvirus 3, Human | 3 | 2015 | 336 | 0.230 |
Why?
|
| Drug Delivery Systems | 2 | 2019 | 380 | 0.230 |
Why?
|
| Oxidative Phosphorylation | 2 | 2016 | 210 | 0.220 |
Why?
|
| Phosphofructokinase-2 | 2 | 2022 | 16 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 2145 | 0.220 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2025 | 81 | 0.220 |
Why?
|
| Proteoglycans | 3 | 2009 | 110 | 0.220 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2004 | 116 | 0.220 |
Why?
|
| Coronary Circulation | 1 | 2025 | 136 | 0.220 |
Why?
|
| Exercise Tolerance | 2 | 2024 | 283 | 0.220 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 4 | 2020 | 153 | 0.220 |
Why?
|
| Capillary Permeability | 6 | 2012 | 134 | 0.220 |
Why?
|
| Histones | 3 | 2021 | 669 | 0.210 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2011 | 370 | 0.210 |
Why?
|
| Pulmonary Wedge Pressure | 4 | 2017 | 67 | 0.210 |
Why?
|
| Sirtuins | 1 | 2024 | 50 | 0.210 |
Why?
|
| Biliary Atresia | 1 | 2005 | 158 | 0.200 |
Why?
|
| Flow Cytometry | 6 | 2013 | 1173 | 0.200 |
Why?
|
| Receptors, Purinergic P2Y | 2 | 2020 | 9 | 0.200 |
Why?
|
| Biomechanical Phenomena | 5 | 2016 | 842 | 0.200 |
Why?
|
| Hexokinase | 1 | 2023 | 18 | 0.200 |
Why?
|
| Oxidative Stress | 6 | 2025 | 1339 | 0.200 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2017 | 561 | 0.200 |
Why?
|
| Antigens, CD | 6 | 2020 | 555 | 0.200 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 288 | 0.200 |
Why?
|
| GTP-Binding Proteins | 2 | 2001 | 153 | 0.200 |
Why?
|
| Chemokine CXCL12 | 3 | 2020 | 89 | 0.200 |
Why?
|
| Case-Control Studies | 8 | 2020 | 3604 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 1997 | 319 | 0.190 |
Why?
|
| Heparan Sulfate Proteoglycans | 2 | 2003 | 24 | 0.190 |
Why?
|
| Congresses as Topic | 1 | 2024 | 221 | 0.190 |
Why?
|
| Hydrogen Peroxide | 3 | 2022 | 336 | 0.190 |
Why?
|
| Liposomes | 3 | 2019 | 250 | 0.190 |
Why?
|
| Proteomics | 4 | 2024 | 1195 | 0.190 |
Why?
|
| Extracellular Fluid | 2 | 2020 | 36 | 0.190 |
Why?
|
| Regional Blood Flow | 3 | 2021 | 514 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 573 | 0.190 |
Why?
|
| Eicosanoids | 2 | 1994 | 58 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2020 | 449 | 0.190 |
Why?
|
| Fructose | 1 | 2023 | 130 | 0.190 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2004 | 106 | 0.190 |
Why?
|
| Valproic Acid | 2 | 2013 | 47 | 0.190 |
Why?
|
| Rats, Wistar | 4 | 2021 | 451 | 0.190 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 2168 | 0.190 |
Why?
|
| Antibodies | 4 | 2019 | 401 | 0.190 |
Why?
|
| Interleukin-4 | 1 | 2023 | 206 | 0.190 |
Why?
|
| DNA | 7 | 2009 | 1463 | 0.190 |
Why?
|
| RNA Interference | 4 | 2017 | 476 | 0.180 |
Why?
|
| SRS-A | 12 | 1990 | 17 | 0.180 |
Why?
|
| Hydroxamic Acids | 2 | 2013 | 94 | 0.180 |
Why?
|
| Dementia, Vascular | 1 | 2022 | 21 | 0.180 |
Why?
|
| Physical Conditioning, Animal | 1 | 2024 | 243 | 0.180 |
Why?
|
| Blood Flow Velocity | 3 | 2019 | 413 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2020 | 161 | 0.180 |
Why?
|
| Cell Culture Techniques | 3 | 2017 | 375 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2021 | 969 | 0.180 |
Why?
|
| Contractile Proteins | 3 | 2000 | 13 | 0.180 |
Why?
|
| Uric Acid | 2 | 2022 | 166 | 0.180 |
Why?
|
| Hyperuricemia | 1 | 2022 | 47 | 0.180 |
Why?
|
| Purines | 1 | 2023 | 187 | 0.180 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2024 | 158 | 0.180 |
Why?
|
| Perfusion Imaging | 2 | 2019 | 65 | 0.180 |
Why?
|
| Aging | 7 | 2019 | 1966 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2021 | 21 | 0.170 |
Why?
|
| Enzyme Inhibitors | 8 | 2022 | 824 | 0.170 |
Why?
|
| Aorta | 7 | 2007 | 429 | 0.170 |
Why?
|
| Actin Cytoskeleton | 2 | 2013 | 103 | 0.170 |
Why?
|
| Water | 3 | 2019 | 469 | 0.170 |
Why?
|
| Interleukin-10 | 1 | 2023 | 309 | 0.170 |
Why?
|
| Apelin | 1 | 2021 | 10 | 0.170 |
Why?
|
| Pentose Phosphate Pathway | 2 | 2020 | 55 | 0.170 |
Why?
|
| Angiofibroma | 1 | 2001 | 6 | 0.170 |
Why?
|
| Hemangiopericytoma | 1 | 2001 | 5 | 0.170 |
Why?
|
| Antagomirs | 2 | 2017 | 12 | 0.170 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2001 | 7 | 0.170 |
Why?
|
| Models, Biological | 4 | 2021 | 1821 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2023 | 415 | 0.170 |
Why?
|
| Carotid Artery Injuries | 2 | 2004 | 39 | 0.170 |
Why?
|
| Muscle Proteins | 4 | 2011 | 244 | 0.170 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 1126 | 0.170 |
Why?
|
| Butyrates | 1 | 2021 | 67 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 3 | 1997 | 156 | 0.160 |
Why?
|
| Cell Adhesion | 3 | 2017 | 455 | 0.160 |
Why?
|
| Prodrugs | 1 | 2021 | 52 | 0.160 |
Why?
|
| Cluster Analysis | 1 | 2022 | 521 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 244 | 0.160 |
Why?
|
| Body Water | 1 | 2000 | 23 | 0.160 |
Why?
|
| Beta vulgaris | 1 | 2020 | 14 | 0.160 |
Why?
|
| Immunomodulation | 2 | 2011 | 101 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 114 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 780 | 0.160 |
Why?
|
| Fibronectins | 2 | 2006 | 136 | 0.160 |
Why?
|
| Stress, Physiological | 3 | 2012 | 453 | 0.160 |
Why?
|
| Adenosine | 2 | 2020 | 255 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2021 | 120 | 0.160 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2020 | 18 | 0.160 |
Why?
|
| Altitude Sickness | 2 | 2015 | 141 | 0.160 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2020 | 19 | 0.160 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2020 | 56 | 0.160 |
Why?
|
| Hypertrophy | 2 | 2018 | 127 | 0.160 |
Why?
|
| Vasoactive Intestinal Peptide | 2 | 2010 | 20 | 0.160 |
Why?
|
| Complement C5 | 1 | 2020 | 33 | 0.160 |
Why?
|
| Biomimetics | 1 | 2020 | 40 | 0.160 |
Why?
|
| Osteoprotegerin | 1 | 2019 | 22 | 0.150 |
Why?
|
| Eicosanoic Acids | 3 | 1989 | 3 | 0.150 |
Why?
|
| Emulsions | 1 | 2019 | 57 | 0.150 |
Why?
|
| Child | 15 | 2023 | 22633 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 442 | 0.150 |
Why?
|
| Adult | 13 | 2025 | 40449 | 0.150 |
Why?
|
| Bone Marrow Cells | 2 | 2020 | 320 | 0.150 |
Why?
|
| Virus Diseases | 2 | 2012 | 216 | 0.150 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 32 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 233 | 0.150 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2020 | 125 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2001 | 127 | 0.150 |
Why?
|
| Culture Media, Serum-Free | 5 | 2004 | 42 | 0.150 |
Why?
|
| Hypertension, Renovascular | 1 | 1999 | 15 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2021 | 161 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 197 | 0.150 |
Why?
|
| Isotope Labeling | 1 | 2020 | 82 | 0.150 |
Why?
|
| Leukotriene B4 | 3 | 2015 | 37 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2020 | 160 | 0.150 |
Why?
|
| Cytoskeleton | 1 | 2000 | 195 | 0.150 |
Why?
|
| Electron Transport Complex I | 2 | 2016 | 42 | 0.150 |
Why?
|
| Complement Factor B | 1 | 2020 | 106 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 173 | 0.150 |
Why?
|
| Pluripotent Stem Cells | 1 | 2020 | 84 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 285 | 0.140 |
Why?
|
| Complement Pathway, Alternative | 1 | 2020 | 122 | 0.140 |
Why?
|
| RNA, Small Interfering | 5 | 2017 | 635 | 0.140 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2012 | 90 | 0.140 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2018 | 8 | 0.140 |
Why?
|
| Endothelins | 4 | 2018 | 63 | 0.140 |
Why?
|
| Respiratory Mucosa | 1 | 2001 | 322 | 0.140 |
Why?
|
| Child, Preschool | 12 | 2021 | 11787 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2021 | 397 | 0.140 |
Why?
|
| Peptides | 3 | 2017 | 995 | 0.140 |
Why?
|
| Urocortins | 1 | 2018 | 24 | 0.140 |
Why?
|
| Protein Isoforms | 2 | 2017 | 402 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 167 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2020 | 477 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2023 | 2115 | 0.140 |
Why?
|
| Arteries | 3 | 2019 | 259 | 0.140 |
Why?
|
| Drug Repositioning | 1 | 2018 | 41 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 2 | 2009 | 178 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2012 | 14 | 0.140 |
Why?
|
| Naphthoquinones | 1 | 2017 | 19 | 0.130 |
Why?
|
| Procollagen | 3 | 1994 | 23 | 0.130 |
Why?
|
| Activating Transcription Factor 6 | 2 | 2021 | 21 | 0.130 |
Why?
|
| Fluorocarbons | 1 | 2019 | 143 | 0.130 |
Why?
|
| Peptides, Cyclic | 1 | 2019 | 275 | 0.130 |
Why?
|
| Immunoblotting | 3 | 2014 | 300 | 0.130 |
Why?
|
| Physical Exertion | 1 | 2018 | 207 | 0.130 |
Why?
|
| Genomics | 1 | 2023 | 834 | 0.130 |
Why?
|
| Echocardiography, Doppler | 1 | 2018 | 115 | 0.130 |
Why?
|
| Estradiol | 1 | 2021 | 533 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2017 | 56 | 0.130 |
Why?
|
| Cell Count | 3 | 2020 | 320 | 0.130 |
Why?
|
| Administration, Inhalation | 4 | 2021 | 574 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 427 | 0.130 |
Why?
|
| Dinoprostone | 3 | 1999 | 178 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2017 | 35 | 0.130 |
Why?
|
| Optical Imaging | 1 | 2017 | 64 | 0.130 |
Why?
|
| Echocardiography | 2 | 2016 | 652 | 0.130 |
Why?
|
| Cell Size | 3 | 2003 | 92 | 0.130 |
Why?
|
| Pyridines | 4 | 2015 | 605 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.120 |
Why?
|
| Endothelial Growth Factors | 2 | 2009 | 64 | 0.120 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2016 | 9 | 0.120 |
Why?
|
| Glucose | 2 | 2023 | 1047 | 0.120 |
Why?
|
| Receptors, Angiotensin | 1 | 1996 | 11 | 0.120 |
Why?
|
| Protein Binding | 4 | 2019 | 2273 | 0.120 |
Why?
|
| Biomarkers | 7 | 2021 | 4271 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 420 | 0.120 |
Why?
|
| Acetylation | 4 | 2021 | 252 | 0.120 |
Why?
|
| Epinephrine | 1 | 1997 | 155 | 0.120 |
Why?
|
| Pyruvic Acid | 1 | 2016 | 55 | 0.120 |
Why?
|
| Cell Respiration | 1 | 2016 | 107 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2017 | 124 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 462 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 461 | 0.120 |
Why?
|
| Mice, Transgenic | 5 | 2020 | 2182 | 0.120 |
Why?
|
| Carbon | 1 | 2017 | 203 | 0.120 |
Why?
|
| Adolescent | 10 | 2021 | 22428 | 0.120 |
Why?
|
| Adaptation, Physiological | 2 | 2018 | 570 | 0.120 |
Why?
|
| Acclimatization | 2 | 2018 | 172 | 0.120 |
Why?
|
| Prognosis | 3 | 2020 | 4282 | 0.120 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2015 | 359 | 0.120 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2015 | 383 | 0.120 |
Why?
|
| Vinculin | 1 | 1995 | 10 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2018 | 226 | 0.110 |
Why?
|
| Activation, Metabolic | 1 | 2015 | 5 | 0.110 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2015 | 49 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 175 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 395 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 4 | 2020 | 178 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2021 | 790 | 0.110 |
Why?
|
| Blood Proteins | 2 | 2012 | 249 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2017 | 247 | 0.110 |
Why?
|
| Dogs | 1 | 2016 | 437 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 1999 | 427 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 98 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2020 | 681 | 0.110 |
Why?
|
| Middle Aged | 10 | 2024 | 35875 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 392 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 72 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 2 | 2009 | 144 | 0.110 |
Why?
|
| Bronchoalveolar Lavage Fluid | 5 | 2017 | 636 | 0.110 |
Why?
|
| Haptoglobins | 1 | 2015 | 66 | 0.110 |
Why?
|
| Receptors, CCR2 | 2 | 2025 | 39 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2016 | 627 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 1054 | 0.110 |
Why?
|
| Cation Transport Proteins | 1 | 2015 | 118 | 0.110 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2014 | 33 | 0.100 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 1496 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 266 | 0.100 |
Why?
|
| Chloride Channels | 1 | 2014 | 34 | 0.100 |
Why?
|
| Leukocyte Common Antigens | 2 | 2011 | 88 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 3540 | 0.100 |
Why?
|
| Receptor, Endothelin B | 2 | 2012 | 48 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2013 | 3 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2017 | 780 | 0.100 |
Why?
|
| Receptor, Endothelin A | 2 | 2012 | 63 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2006 | 167 | 0.100 |
Why?
|
| Schistosoma mansoni | 2 | 2024 | 41 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2014 | 61 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 66 | 0.100 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2005 | 27 | 0.100 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2014 | 126 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 2925 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 64 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2003 | 905 | 0.100 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2013 | 11 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2014 | 661 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 112 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 2027 | 0.100 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 80 | 0.100 |
Why?
|
| Platelet Factor 4 | 2 | 2025 | 36 | 0.100 |
Why?
|
| Veins | 1 | 2013 | 68 | 0.100 |
Why?
|
| Chemokines | 2 | 2015 | 218 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2012 | 16 | 0.100 |
Why?
|
| Thromboxane B2 | 6 | 2009 | 23 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 152 | 0.100 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2014 | 120 | 0.090 |
Why?
|
| Somatomedins | 2 | 1990 | 28 | 0.090 |
Why?
|
| Exercise | 1 | 2005 | 2201 | 0.090 |
Why?
|
| Polymers | 1 | 2017 | 499 | 0.090 |
Why?
|
| Middle Cerebral Artery | 1 | 2012 | 56 | 0.090 |
Why?
|
| Heart Arrest | 1 | 1997 | 407 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 207 | 0.090 |
Why?
|
| Temporal Arteries | 1 | 2012 | 43 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2012 | 20 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 50 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2012 | 31 | 0.090 |
Why?
|
| Ephrin-A1 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.090 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2012 | 26 | 0.090 |
Why?
|
| Receptor, EphA2 | 1 | 2012 | 17 | 0.090 |
Why?
|
| Nucleotides | 2 | 2002 | 128 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 102 | 0.090 |
Why?
|
| Cause of Death | 1 | 2014 | 471 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2015 | 315 | 0.090 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2004 | 58 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2014 | 72 | 0.090 |
Why?
|
| Apyrase | 1 | 2011 | 26 | 0.090 |
Why?
|
| Xanthine Oxidase | 1 | 2011 | 79 | 0.090 |
Why?
|
| Elastic Tissue | 1 | 2011 | 10 | 0.090 |
Why?
|
| Fibrillar Collagens | 1 | 2011 | 14 | 0.090 |
Why?
|
| 5'-Nucleotidase | 1 | 2011 | 49 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1253 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 541 | 0.090 |
Why?
|
| Laminin | 2 | 2009 | 72 | 0.090 |
Why?
|
| Heart Transplantation | 2 | 2015 | 736 | 0.090 |
Why?
|
| DNA Primers | 2 | 2011 | 512 | 0.080 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2018 | 691 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 200 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2011 | 58 | 0.080 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2010 | 8 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2001 | 269 | 0.080 |
Why?
|
| World Health Organization | 1 | 2011 | 105 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2021 | 7990 | 0.080 |
Why?
|
| Cell Cycle Proteins | 3 | 2020 | 628 | 0.080 |
Why?
|
| Myosin Heavy Chains | 4 | 2014 | 185 | 0.080 |
Why?
|
| Analysis of Variance | 4 | 2018 | 1306 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2015 | 707 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 508 | 0.080 |
Why?
|
| Cyclic AMP | 3 | 2014 | 209 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 307 | 0.080 |
Why?
|
| Cloning, Molecular | 3 | 2000 | 540 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2004 | 136 | 0.080 |
Why?
|
| Base Sequence | 3 | 2008 | 2190 | 0.080 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2009 | 12 | 0.080 |
Why?
|
| Bronchi | 3 | 2013 | 267 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2009 | 390 | 0.080 |
Why?
|
| Age Factors | 4 | 2019 | 3333 | 0.080 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2009 | 4 | 0.080 |
Why?
|
| Elasticity | 4 | 2019 | 184 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2009 | 36 | 0.080 |
Why?
|
| Alveolar Epithelial Cells | 2 | 2023 | 120 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 266 | 0.080 |
Why?
|
| Thiazolidinediones | 2 | 2009 | 138 | 0.080 |
Why?
|
| Iloprost | 1 | 2009 | 44 | 0.080 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2009 | 31 | 0.080 |
Why?
|
| Arachidonic Acids | 3 | 1987 | 43 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 87 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 151 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 5 | 2016 | 1257 | 0.070 |
Why?
|
| Myofibroblasts | 1 | 2011 | 143 | 0.070 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 47 | 0.070 |
Why?
|
| Pyrrolizidine Alkaloids | 3 | 1987 | 11 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2010 | 235 | 0.070 |
Why?
|
| Culture Media | 1 | 2009 | 161 | 0.070 |
Why?
|
| Ribosomal Protein S6 | 2 | 2010 | 18 | 0.070 |
Why?
|
| Overweight | 1 | 2014 | 609 | 0.070 |
Why?
|
| Lactic Acid | 2 | 2023 | 302 | 0.070 |
Why?
|
| Bradykinin | 2 | 2001 | 48 | 0.070 |
Why?
|
| Ventricular Pressure | 3 | 2015 | 52 | 0.070 |
Why?
|
| Lung Injury | 1 | 2012 | 237 | 0.070 |
Why?
|
| Calcium Signaling | 1 | 2010 | 251 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2011 | 361 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2012 | 770 | 0.070 |
Why?
|
| Trachea | 1 | 2010 | 261 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-sis | 3 | 2012 | 39 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 267 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3863 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 1387 | 0.070 |
Why?
|
| Adenylyl Cyclases | 3 | 2014 | 60 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2009 | 206 | 0.070 |
Why?
|
| Heart | 3 | 2020 | 636 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 1990 | 221 | 0.070 |
Why?
|
| Respiratory System | 1 | 2009 | 149 | 0.070 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Acute Disease | 3 | 2005 | 1030 | 0.070 |
Why?
|
| Embryo, Mammalian | 2 | 2000 | 232 | 0.070 |
Why?
|
| Indoles | 4 | 2018 | 501 | 0.070 |
Why?
|
| Muscle Development | 3 | 1999 | 116 | 0.070 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2008 | 71 | 0.070 |
Why?
|
| Reference Values | 3 | 1994 | 797 | 0.070 |
Why?
|
| Cerebral Ventricles | 1 | 1987 | 54 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 675 | 0.070 |
Why?
|
| Platelet Activating Factor | 1 | 1987 | 49 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 93 | 0.070 |
Why?
|
| Porosity | 2 | 2018 | 96 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5408 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 2583 | 0.060 |
Why?
|
| Acetylcholine | 3 | 1993 | 204 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1997 | 153 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2016 | 1382 | 0.060 |
Why?
|
| Imidazoles | 2 | 2015 | 254 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 758 | 0.060 |
Why?
|
| Pertussis Toxin | 2 | 2010 | 24 | 0.060 |
Why?
|
| Epithelial Cells | 4 | 2010 | 1125 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 14105 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2014 | 204 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 676 | 0.060 |
Why?
|
| Drug Carriers | 2 | 2018 | 130 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 1370 | 0.060 |
Why?
|
| Chemokine CCL5 | 2 | 2020 | 41 | 0.060 |
Why?
|
| Sulfonamides | 2 | 2012 | 580 | 0.060 |
Why?
|
| Organ Size | 2 | 2000 | 463 | 0.060 |
Why?
|
| Tenascin | 1 | 2006 | 15 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2009 | 784 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2019 | 11679 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2006 | 21 | 0.060 |
Why?
|
| Biliary Tract | 1 | 2005 | 14 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2013 | 1501 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2006 | 65 | 0.060 |
Why?
|
| Calcium | 2 | 2010 | 1183 | 0.060 |
Why?
|
| Sheep | 5 | 1998 | 880 | 0.060 |
Why?
|
| Autopsy | 1 | 2005 | 94 | 0.060 |
Why?
|
| Cell Fusion | 2 | 2008 | 49 | 0.060 |
Why?
|
| Hydrodynamics | 1 | 2025 | 47 | 0.060 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 4 | 1990 | 18 | 0.060 |
Why?
|
| Therapeutic Irrigation | 7 | 1987 | 69 | 0.060 |
Why?
|
| Maleimides | 3 | 2000 | 21 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2006 | 147 | 0.060 |
Why?
|
| Compliance | 1 | 2005 | 49 | 0.060 |
Why?
|
| Rats, Mutant Strains | 2 | 2021 | 20 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2006 | 125 | 0.060 |
Why?
|
| Protein Biosynthesis | 2 | 2003 | 458 | 0.050 |
Why?
|
| Monocrotaline | 4 | 2017 | 32 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2005 | 147 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2005 | 100 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 416 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2018 | 651 | 0.050 |
Why?
|
| Complement C5a | 1 | 2024 | 54 | 0.050 |
Why?
|
| Complement C3a | 1 | 2024 | 40 | 0.050 |
Why?
|
| Cell Line | 4 | 2017 | 2882 | 0.050 |
Why?
|
| Lipid Peroxidation | 2 | 2017 | 160 | 0.050 |
Why?
|
| Cadherins | 2 | 2009 | 201 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1995 | 221 | 0.050 |
Why?
|
| Schistosomiasis mansoni | 1 | 2024 | 25 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 1999 | 74 | 0.050 |
Why?
|
| Yin-Yang | 1 | 2004 | 1 | 0.050 |
Why?
|
| Receptors, Purinergic | 2 | 2016 | 20 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2004 | 59 | 0.050 |
Why?
|
| Rats, Inbred Strains | 7 | 1990 | 321 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2006 | 376 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 336 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2010 | 710 | 0.050 |
Why?
|
| Kidney | 3 | 2012 | 1495 | 0.050 |
Why?
|
| Blood Physiological Phenomena | 1 | 2003 | 12 | 0.050 |
Why?
|
| Pericytes | 1 | 2024 | 36 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2004 | 205 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 83 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2005 | 313 | 0.050 |
Why?
|
| Lymphokines | 1 | 2003 | 130 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2015 | 138 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2003 | 67 | 0.050 |
Why?
|
| Catheterization | 2 | 2004 | 183 | 0.050 |
Why?
|
| In Vitro Techniques | 6 | 2001 | 1047 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2003 | 56 | 0.050 |
Why?
|
| Protein Kinase C beta | 2 | 2000 | 21 | 0.050 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2002 | 11 | 0.050 |
Why?
|
| Diethylcarbamazine | 4 | 1986 | 4 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1985 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 49 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2025 | 372 | 0.050 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2002 | 56 | 0.050 |
Why?
|
| Brain Injuries | 1 | 1987 | 507 | 0.050 |
Why?
|
| Sodium Channels | 1 | 2002 | 63 | 0.050 |
Why?
|
| Leukotrienes | 2 | 1994 | 27 | 0.050 |
Why?
|
| Prostaglandins | 2 | 1994 | 94 | 0.050 |
Why?
|
| Stroke | 1 | 2011 | 1256 | 0.050 |
Why?
|
| Biopsy | 1 | 2005 | 1075 | 0.040 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 338 | 0.040 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2001 | 4 | 0.040 |
Why?
|
| Biology | 1 | 2023 | 91 | 0.040 |
Why?
|
| Thrombin | 1 | 2023 | 166 | 0.040 |
Why?
|
| Quinuclidines | 1 | 2001 | 11 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 2004 | 2930 | 0.040 |
Why?
|
| Heparin | 2 | 1997 | 244 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2001 | 58 | 0.040 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2001 | 8 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2002 | 112 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2002 | 162 | 0.040 |
Why?
|
| Transfection | 2 | 2015 | 940 | 0.040 |
Why?
|
| Substance P | 1 | 2001 | 39 | 0.040 |
Why?
|
| Anaerobiosis | 1 | 2021 | 64 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2025 | 583 | 0.040 |
Why?
|
| Sodium | 1 | 2002 | 197 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 8 | 0.040 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2021 | 17 | 0.040 |
Why?
|
| Zebrafish | 1 | 2006 | 528 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2001 | 15 | 0.040 |
Why?
|
| Systole | 1 | 2021 | 178 | 0.040 |
Why?
|
| Nitroprusside | 2 | 1993 | 72 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2001 | 17 | 0.040 |
Why?
|
| Transcription Factor CHOP | 1 | 2021 | 32 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 33 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2021 | 81 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 102 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 84 | 0.040 |
Why?
|
| Parabiosis | 1 | 2020 | 11 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 96 | 0.040 |
Why?
|
| Respirovirus | 1 | 2000 | 6 | 0.040 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 2000 | 10 | 0.040 |
Why?
|
| Methionine | 1 | 2001 | 162 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 86 | 0.040 |
Why?
|
| Pancreatic Elastase | 1 | 2000 | 55 | 0.040 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2000 | 32 | 0.040 |
Why?
|
| Chromones | 3 | 2013 | 42 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2021 | 95 | 0.040 |
Why?
|
| Intermediate Filament Proteins | 1 | 2000 | 57 | 0.040 |
Why?
|
| Obesity | 1 | 2014 | 3077 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2000 | 62 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 1995 | 594 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2021 | 186 | 0.040 |
Why?
|
| Blood Gas Analysis | 2 | 1993 | 83 | 0.040 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2020 | 12 | 0.040 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2020 | 10 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2006 | 618 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 863 | 0.040 |
Why?
|
| Polymethacrylic Acids | 1 | 2020 | 61 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 49 | 0.040 |
Why?
|
| Mutation | 1 | 2011 | 4089 | 0.040 |
Why?
|
| Piperidines | 1 | 2001 | 217 | 0.040 |
Why?
|
| Hyperbaric Oxygenation | 2 | 2011 | 39 | 0.040 |
Why?
|
| Nitrates | 1 | 2020 | 100 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2000 | 137 | 0.040 |
Why?
|
| Phenylpropionates | 1 | 2019 | 27 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 144 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 83 | 0.040 |
Why?
|
| Macaca radiata | 1 | 1999 | 15 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 433 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 673 | 0.040 |
Why?
|
| Phospholipases A | 1 | 1999 | 98 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2020 | 92 | 0.040 |
Why?
|
| Pyridazines | 1 | 2019 | 57 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 1217 | 0.040 |
Why?
|
| Anticoagulants | 2 | 1999 | 722 | 0.040 |
Why?
|
| Pregnancy | 4 | 1999 | 7190 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 151 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 84 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 1999 | 165 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 3409 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 194 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 82 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 64 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2001 | 405 | 0.040 |
Why?
|
| Aged | 5 | 2019 | 25913 | 0.040 |
Why?
|
| Glycosaminoglycans | 1 | 2019 | 74 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 205 | 0.040 |
Why?
|
| Partial Pressure | 1 | 1998 | 31 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2021 | 266 | 0.040 |
Why?
|
| Morpholines | 2 | 2013 | 128 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2018 | 59 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 139 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 338 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2018 | 36 | 0.030 |
Why?
|
| Bronchiolitis | 1 | 1999 | 87 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1999 | 327 | 0.030 |
Why?
|
| Immune System | 1 | 2019 | 179 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 405 | 0.030 |
Why?
|
| Thymidine | 2 | 1995 | 60 | 0.030 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 24 | 0.030 |
Why?
|
| Cell Death | 1 | 2000 | 383 | 0.030 |
Why?
|
| Arachidonic Acid | 3 | 1987 | 101 | 0.030 |
Why?
|
| Lim Kinases | 1 | 2017 | 5 | 0.030 |
Why?
|
| Smad5 Protein | 1 | 2017 | 7 | 0.030 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2017 | 21 | 0.030 |
Why?
|
| Smad1 Protein | 1 | 2017 | 17 | 0.030 |
Why?
|
| Lipids | 1 | 2023 | 710 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 210 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 177 | 0.030 |
Why?
|
| Blood | 2 | 1995 | 109 | 0.030 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 45 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2018 | 107 | 0.030 |
Why?
|
| Rabbits | 2 | 2014 | 648 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2017 | 40 | 0.030 |
Why?
|
| Kinetics | 1 | 2001 | 1627 | 0.030 |
Why?
|
| Muscle, Smooth | 3 | 2009 | 153 | 0.030 |
Why?
|
| Symporters | 1 | 2017 | 48 | 0.030 |
Why?
|
| Pyrroles | 1 | 2018 | 217 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 338 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 724 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 427 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2003 | 757 | 0.030 |
Why?
|
| Polyethyleneimine | 1 | 2017 | 18 | 0.030 |
Why?
|
| Polyglycolic Acid | 1 | 2017 | 44 | 0.030 |
Why?
|
| Mammals | 1 | 1999 | 293 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1997 | 93 | 0.030 |
Why?
|
| Myosins | 1 | 1997 | 136 | 0.030 |
Why?
|
| Incidence | 1 | 2004 | 2879 | 0.030 |
Why?
|
| Chromatin | 1 | 2021 | 561 | 0.030 |
Why?
|
| Homeostasis | 2 | 2015 | 640 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2017 | 109 | 0.030 |
Why?
|
| Microspheres | 1 | 2017 | 142 | 0.030 |
Why?
|
| Hemolysis | 1 | 2018 | 243 | 0.030 |
Why?
|
| Enzyme Repression | 1 | 2016 | 6 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1998 | 242 | 0.030 |
Why?
|
| Autoradiography | 1 | 1996 | 64 | 0.030 |
Why?
|
| Photochemical Processes | 1 | 2017 | 108 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 392 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 171 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2020 | 576 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 1996 | 62 | 0.030 |
Why?
|
| Guinea Pigs | 3 | 1985 | 159 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2015 | 25 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2015 | 22 | 0.030 |
Why?
|
| Animals, Congenic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2015 | 36 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Surface Properties | 1 | 2017 | 410 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2015 | 28 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 854 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 56 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 530 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 411 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 2029 | 0.030 |
Why?
|
| Capillaries | 1 | 1996 | 124 | 0.030 |
Why?
|
| Arterioles | 1 | 2015 | 56 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2015 | 66 | 0.030 |
Why?
|
| Gestational Age | 1 | 1999 | 975 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 81 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2015 | 124 | 0.030 |
Why?
|
| Phosphofructokinase-1 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 1995 | 117 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 268 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 132 | 0.030 |
Why?
|
| GTP Cyclohydrolase | 1 | 2014 | 10 | 0.030 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2014 | 16 | 0.030 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 61 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 851 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1995 | 114 | 0.030 |
Why?
|
| Species Specificity | 2 | 2011 | 574 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1994 | 93 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2014 | 39 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2014 | 48 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 1994 | 74 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2012 | 179 | 0.030 |
Why?
|
| Fibrinogen | 1 | 1995 | 177 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2014 | 92 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1995 | 103 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 321 | 0.030 |
Why?
|
| Exosomes | 1 | 2015 | 104 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 1995 | 219 | 0.030 |
Why?
|
| Cell Migration Assays | 1 | 2014 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 847 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2014 | 33 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 95 | 0.030 |
Why?
|
| Resuscitation | 1 | 1997 | 302 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2015 | 164 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1053 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3671 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 341 | 0.030 |
Why?
|
| Animals, Genetically Modified | 2 | 2006 | 250 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 183 | 0.030 |
Why?
|
| Biological Assay | 2 | 1985 | 128 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 650 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2014 | 217 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2014 | 117 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 85 | 0.020 |
Why?
|
| Cognition | 1 | 2022 | 1266 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 131 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 182 | 0.020 |
Why?
|
| Air Pressure | 1 | 1993 | 3 | 0.020 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 66 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2014 | 397 | 0.020 |
Why?
|
| Protein Conformation | 2 | 2008 | 946 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 2013 | 37 | 0.020 |
Why?
|
| Connective Tissue Diseases | 1 | 2014 | 84 | 0.020 |
Why?
|
| Ramipril | 1 | 2012 | 6 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1694 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 209 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1993 | 199 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 614 | 0.020 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2015 | 219 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2012 | 114 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2012 | 33 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1266 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2012 | 23 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2012 | 32 | 0.020 |
Why?
|
| Physical Examination | 1 | 2014 | 239 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1993 | 196 | 0.020 |
Why?
|
| Zinc | 1 | 2015 | 295 | 0.020 |
Why?
|
| Spin Labels | 1 | 2012 | 59 | 0.020 |
Why?
|
| Iron | 1 | 2015 | 359 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1989 | 187 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 276 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1995 | 442 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2015 | 338 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 1329 | 0.020 |
Why?
|
| Prostaglandins F | 2 | 2009 | 15 | 0.020 |
Why?
|
| Alleles | 1 | 2015 | 879 | 0.020 |
Why?
|
| Embolism, Air | 1 | 1992 | 14 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2012 | 76 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2004 | 2155 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 204 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 36 | 0.020 |
Why?
|
| Telomerase | 1 | 2014 | 248 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 116 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 645 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 196 | 0.020 |
Why?
|
| Excitation Contraction Coupling | 1 | 2011 | 17 | 0.020 |
Why?
|
| Dextrans | 1 | 2011 | 86 | 0.020 |
Why?
|
| Purinergic Agonists | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 174 | 0.020 |
Why?
|
| Airway Resistance | 1 | 1991 | 38 | 0.020 |
Why?
|
| Benzamides | 1 | 2012 | 224 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 42 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1992 | 354 | 0.020 |
Why?
|
| Pyridoxal Phosphate | 1 | 2010 | 25 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2010 | 44 | 0.020 |
Why?
|
| Azo Compounds | 1 | 2010 | 30 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 596 | 0.020 |
Why?
|
| Nitrosation | 1 | 2010 | 8 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 142 | 0.020 |
Why?
|
| Constriction | 1 | 1990 | 47 | 0.020 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 1987 | 35 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 708 | 0.020 |
Why?
|
| Foreign-Body Migration | 1 | 1990 | 32 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 354 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2010 | 37 | 0.020 |
Why?
|
| Calcimycin | 1 | 1989 | 36 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1990 | 40 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 1990 | 46 | 0.020 |
Why?
|
| Sutures | 1 | 1990 | 64 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1992 | 191 | 0.020 |
Why?
|
| Cesarean Section | 1 | 1992 | 224 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2015 | 983 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2010 | 154 | 0.020 |
Why?
|
| Transport Vesicles | 1 | 2009 | 21 | 0.020 |
Why?
|
| Chemokines, CX3C | 1 | 2009 | 10 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 222 | 0.020 |
Why?
|
| Colitis | 1 | 2012 | 280 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 8265 | 0.020 |
Why?
|
| Bronchoconstriction | 1 | 2009 | 29 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2009 | 24 | 0.020 |
Why?
|
| E-Selectin | 1 | 2009 | 61 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 1003 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 56 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2009 | 93 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
|
| Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 1990 | 174 | 0.020 |
Why?
|
| Ductus Arteriosus | 1 | 1988 | 72 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 2730 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2012 | 961 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 123 | 0.020 |
Why?
|
| Indomethacin | 2 | 1985 | 76 | 0.020 |
Why?
|
| Hyperoxia | 1 | 2009 | 99 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1994 | 1886 | 0.020 |
Why?
|
| Prostaglandins D | 1 | 1987 | 1 | 0.020 |
Why?
|
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 1987 | 5 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 1987 | 33 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2012 | 532 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1987 | 22 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2009 | 113 | 0.020 |
Why?
|
| RNA | 2 | 1991 | 940 | 0.020 |
Why?
|
| Pneumothorax | 1 | 1988 | 51 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2013 | 926 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1985 | 316 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 914 | 0.020 |
Why?
|
| Thrombosis | 1 | 2011 | 393 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 876 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 570 | 0.020 |
Why?
|
| Neutrophils | 1 | 2012 | 1134 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 355 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 1025 | 0.020 |
Why?
|
| Hospitalization | 1 | 1997 | 2433 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2363 | 0.020 |
Why?
|
| Colorado | 1 | 2016 | 4564 | 0.010 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2006 | 23 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 1833 | 0.010 |
Why?
|
| Ileum | 2 | 1984 | 111 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2006 | 32 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 5960 | 0.010 |
Why?
|
| Arachidonate Lipoxygenases | 1 | 1985 | 1 | 0.010 |
Why?
|
| Lipoxygenase | 1 | 1985 | 15 | 0.010 |
Why?
|
| Neoplasms | 1 | 2021 | 2875 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2006 | 226 | 0.010 |
Why?
|
| COP9 Signalosome Complex | 1 | 2004 | 5 | 0.010 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2004 | 16 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 1982 | 0.010 |
Why?
|
| Cullin Proteins | 1 | 2004 | 13 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2004 | 49 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 110 | 0.010 |
Why?
|
| Senecio | 1 | 1983 | 3 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1983 | 18 | 0.010 |
Why?
|
| Androstadienes | 1 | 2004 | 76 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2004 | 86 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2003 | 19 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 80 | 0.010 |
Why?
|
| Isoxazoles | 1 | 2003 | 53 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2004 | 105 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10779 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2003 | 32 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2003 | 35 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2919 | 0.010 |
Why?
|
| Multiprotein Complexes | 1 | 2004 | 172 | 0.010 |
Why?
|
| Thiophenes | 1 | 2003 | 128 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2004 | 164 | 0.010 |
Why?
|
| Epithelial Sodium Channels | 1 | 2002 | 21 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 192 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 919 | 0.010 |
Why?
|
| Sirolimus | 1 | 2004 | 281 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2002 | 218 | 0.010 |
Why?
|
| Palliative Care | 1 | 1990 | 1002 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 321 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 34 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 417 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 459 | 0.010 |
Why?
|
| Serotonin | 1 | 2003 | 293 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 750 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 1098 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1999 | 53 | 0.010 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 1998 | 12 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1997 | 17066 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1999 | 182 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 737 | 0.010 |
Why?
|
| HIV Infections | 1 | 2014 | 3154 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 1998 | 69 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 2194 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1997 | 37 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1997 | 312 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 974 | 0.010 |
Why?
|
| Virus Replication | 1 | 1999 | 529 | 0.010 |
Why?
|
| Calreticulin | 1 | 1995 | 22 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1995 | 85 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 1986 | 131 | 0.010 |
Why?
|
| Lectins | 1 | 1995 | 44 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 327 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1999 | 688 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 331 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1995 | 224 | 0.010 |
Why?
|
| Catalysis | 1 | 1995 | 322 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1992 | 68 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1995 | 706 | 0.010 |
Why?
|
| Biophysics | 1 | 1992 | 74 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 141 | 0.010 |
Why?
|
| Lymph | 1 | 1992 | 31 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1995 | 699 | 0.010 |
Why?
|
| Atmospheric Pressure | 1 | 1991 | 26 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 84 | 0.010 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1991 | 43 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 1991 | 72 | 0.010 |
Why?
|
| RNA Probes | 1 | 1989 | 12 | 0.000 |
Why?
|
| Body Fluids | 1 | 1990 | 70 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1990 | 357 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1989 | 154 | 0.000 |
Why?
|
| Pleural Diseases | 1 | 1988 | 23 | 0.000 |
Why?
|
| Thrombin Time | 1 | 1987 | 11 | 0.000 |
Why?
|
| Partial Thromboplastin Time | 1 | 1987 | 50 | 0.000 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1986 | 85 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 165 | 0.000 |
Why?
|
| Radiography | 1 | 1988 | 844 | 0.000 |
Why?
|
| Food Deprivation | 1 | 1985 | 27 | 0.000 |
Why?
|
| Hematocrit | 1 | 1985 | 108 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1984 | 62 | 0.000 |
Why?
|
| Foam Cells | 1 | 1983 | 17 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1988 | 1489 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1983 | 415 | 0.000 |
Why?
|
| Perfusion | 1 | 1984 | 250 | 0.000 |
Why?
|
| Body Weight | 1 | 1985 | 976 | 0.000 |
Why?
|
| Asthma | 1 | 1989 | 1767 | 0.000 |
Why?
|